Recently, the prestigious list of the "2022 China Healthcare Industry Investment and Financing Glory List" was announced by CHC Healthcare Consulting in collaboration with CITIC Securities. Keythera Biopharmaceuticals stood out and was honored with the "Top 15 Best Newcomer Award for Annual Healthcare Enterprises."
Keythera Biopharmaceuticals specializes in the development of small molecule innovative drugs, focusing on the fields of oncology and autoimmune diseases. With its self-built intelligent drug screening platform, the company carries out innovative research and development at the source with high quality and efficiency. By addressing the pain points of homogenized competition in the current pharmaceutical industry, Keythera Biopharmaceuticals achieves differentiation in its product pipeline.
Background of the list:
The "China Healthcare Industry Investment and Financing Glory Awards" is jointly launched by CHC Healthcare Consulting and CITIC Securities. Through data analysis, horizontal comparison, and comprehensive evaluation, outstanding participants in the healthcare industry's development, investment, and financing fields are selected for the previous year. This includes investment institutions, investors, and innovative enterprises, among others, to recognize their contributions and establish industry benchmarks. Over the past five years, the Glory Awards have become an important indicator for the development and investment in China's healthcare industry.
0512-63020039
info@keytherapharma.com
Unit B2-508, Bio-Bay, 218 Xinghu Street, SIP, Suzhou, Jiangsu, China
苏公网安备32059002005508号
